ruxolitinib cream
ApprovedTerminated 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atopic Dermatitis
Conditions
Atopic Dermatitis
Trial Timeline
Mar 16, 2023 → Jan 22, 2025
NCT ID
NCT05696392About ruxolitinib cream
ruxolitinib cream is a approved stage product being developed by Incyte for Atopic Dermatitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05696392. Target conditions include Atopic Dermatitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07049575 | Phase 1 | Recruiting |
| NCT06259669 | Pre-clinical | Recruiting |
| NCT05750823 | Phase 2 | Completed |
| NCT05696392 | Approved | Terminated |
| NCT05456529 | Phase 3 | Completed |
| NCT05034822 | Phase 1 | Completed |
| NCT04839380 | Phase 2 | Completed |
| NCT03920852 | Phase 1 | Completed |
Competing Products
20 competing products in Atopic Dermatitis